Kaufman J, et al.. Community-acquired acute renal failure. Am J Kidney Dis 1991; 17:191–198. doi: 10.1016/s0272-6386(12)81128-0
Nash K, et al.. Hospital-acquired renal insufficiency. Am J Kidney Dis 2002; 39:930–936. doi: 10.1053/ajkd.2002.32766
Bellomo R. The epidemiology of acute renal failure: 1975 versus 2005. Curr Opin Crit Care 2006; 12:557–560. doi: 10.1097/01.ccx.0000247443.86628.68
Kohli HS, et al.. Treatment-related acute renal failure in the elderly: a hospital-based prospective study. Nephrol Dial Transplant 2000; 15:212–217. doi: 10.1093/ndt/15.2.212
Mehta RL, et al.. Spectrum of acute renal failure in the intensive care unit: The PICARD experience. Kidney Int 2004; 66:1613–1621. doi: 10.1111/j.1523-1755.2004.00927.x
Uchino S, et al.. Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 2005; 294:813–818. doi: 10.1001/jama.294.7.813
Hoste EAJ, et al.. Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. Intensive Care Med 2015; 41:1411–1423. doi: 10.1007/s00134-015-3934-7
Radhakrishnan J, Perazella MA. Drug-induced glomerular disease: Attention required! Clin J Am Soc Nephrol 2015; 10:1287–1290. doi: 10.2215/CJN.01010115
Markowitz GS, et al.. Drug-induced glomerular disease: Direct cellular injury. Clin J Am Soc Nephrol 2015; 7:1292–1300. doi: 10.2215/CJN.00860115
Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis 2015; 66:857−868. doi: 10.1053/j.ajkd.2015.02.340
Palma LMP, et al.. Complement in secondary thrombotic microangiopathy. Kidney Int Rep 2021; 6:11−23. doi: 10.1016/j.ekir.2020.10.009
Nasr SH, D’Agati VD. Nodular glomerulosclerosis in the nondiabetic smoker. J Am Soc Nephrol 2007; 18:2032–2036. doi: 10.1681/ASN.2006121328
Markowitz GS, et al.. Idiopathic nodular glomerulosclerosis is a distinct clinicopathologic entity linked to hypertension and smoking. Hum Pathol 2002; 33:826–835. doi: 10.1053/hupa.2002.126189
Kim JS, et al.. Concurrent drug-induced linear immunoglobulin A dermatosis and immunoglobulin A nephropathy. Ann Dermatol 2015; 27:315−318. doi: 10.5021/ad.2015.27.3.315
Hogan JJ, et al.. Drug-induced glomerular disease: Immune-mediated injury. Clin J Am Soc Nephrol 2015; 10:1300–1310. doi: 10.2215/CJN.01910215
Xiao X, Chang C. Diagnosis and classification of drug-induced autoimmunity (DIA). J Autoimmun 2014; 48–49:66–72. doi: 10.1016/j.jaut.2014.01.005
Izzedine H, et al.. Drug-induced glomerulopathies. Expert Opin Drug Saf 2006; 5:95–106. doi: 10.1517/14740338.5.1.95
Kaneko T, et al.. A case of gefitinib-associated membranous nephropathy in treatment for pulmonary adenocarcinoma. CEN Case Rep 2015; 4:31−37. doi: 10.1007/s13730-014-0135-0
Lin JS, et al.. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer 2020; 8:e001287. doi: 10.1136/jitc-2020-001287
Radford MG Jr., et al.. Reversible membranous nephropathy associated with the use of nonsteroidal anti-inflammatory drugs. JAMA 1996; 276:466–469. doi: 10.1001/jama.1996.03540060042033